Unione Europea - spagnolo - EMA (European Medicines Agency)

pfizer europe ma eeig - talazoparib - neoplasias de la mama - agentes antineoplásicos - talzenna está indicado como monoterapia para el tratamiento de pacientes adultos con línea germinal mutaciones brca1/2, que han her2-negativo localmente avanzado o metastásico, el cáncer de mama. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. los pacientes con receptores hormonales (rh) positivo de cáncer de mama deben haber sido tratadas con un endocrino antes de la terapia basada en, o ser considerados no aptos para el sistema endocrino de la terapia basada en.

Unione Europea - spagnolo - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - agentes antineoplásicos - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Unione Europea - spagnolo - EMA (European Medicines Agency)

amgen europe bv - sotorasib - carcinoma, pulmón no microcítico - agentes antineoplásicos - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Uruguay - spagnolo - Ministerio de Salud (Dirección Oficina Central)

scienza uruguay - comprimido recubierto - lapatinib 250 mg comprimido

Perù - spagnolo - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - trastuzumab emtansina - polvo para concentrado para solucion para perfusion - 160 mg - por vial - - trastuzumab emtansine

Perù - spagnolo - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - trastuzumab emtansina - polvo para concentrado para solucion para perfusion - 100 mg - por vial - - trastuzumab emtansine

Perù - spagnolo - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

glaxosmithkline peru s.a. - clorhidrato de pazopanib; - tableta recubierta - por tableta; clorhidrato de pazopanib 216.700000 mg; - pazopanib

Perù - spagnolo - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

novartis biosciences peru s.a. - clorhidrato de pazopanib; - tableta recubierta - por tableta; clorhidrato de pazopanib 216.700000 mg; - pazopanib

Perù - spagnolo - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

glaxosmithkline peru s.a. - pazopanib; - tableta recubierta - por tableta; pazopanib 433.400000 mg; - pazopanib

Perù - spagnolo - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

novartis biosciences peru s.a. - droguerÍa - pazopanib; - tableta recubierta - por tableta - - pazopanib